Lunac Therapeutics
Leeds, GB · 1 known investors
LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.
BiotechHealthtechMedical Devices
Founders & leadership
PH
Professor Helen PhilippouScientific Founder
DR
Dr. Richard FosterScientific Founder
Investors · 1
Companies House · registry record
View on Companies House ↗Insolvency historyAccounts overdueConfirmation statement overdue
- Registered name
- LUNAC THERAPEUTICS LIMITED
- Company number
- 11317849
- Status
- Liquidation
- Company type
- Private limited company
- Incorporated
- 18 Apr 2018
- Registered office
- 29 Craven Street, London, WC2N 5NT
- Nature of business (SIC)
- 72190 — Other research and experimental development on natural sciences and engineering
- Accounts
- last made up to 31 May 2024 · next due 28 Feb 2026
- Confirmation statement
- last made up to 17 Apr 2025 · next due 1 May 2026
Current officers · 4
- Mary Eugenie Canning — director, appointed 20 Sept 2019
- Peter Michael Finan — director, appointed 20 Sept 2019
- Helen Philippou — director, appointed 18 Apr 2018
- Mervyn Turner — director, appointed 4 Oct 2019
Source: Companies House public register · retrieved 3 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.